KR100502701B1 - 사이클린 d1 과발현에 의해 매개되는, 진핵 세포에서의목적 단백질의 과발현 - Google Patents
사이클린 d1 과발현에 의해 매개되는, 진핵 세포에서의목적 단백질의 과발현 Download PDFInfo
- Publication number
- KR100502701B1 KR100502701B1 KR10-2001-7001843A KR20017001843A KR100502701B1 KR 100502701 B1 KR100502701 B1 KR 100502701B1 KR 20017001843 A KR20017001843 A KR 20017001843A KR 100502701 B1 KR100502701 B1 KR 100502701B1
- Authority
- KR
- South Korea
- Prior art keywords
- cyclin
- cell
- cells
- protein
- delete delete
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 80
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 53
- 210000003527 eukaryotic cell Anatomy 0.000 title claims abstract description 7
- 102000016736 Cyclin Human genes 0.000 title description 17
- 108050006400 Cyclin Proteins 0.000 title description 17
- 230000002018 overexpression Effects 0.000 title description 8
- 230000001404 mediated effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 152
- 230000014509 gene expression Effects 0.000 claims abstract description 72
- 108090000259 Cyclin D Proteins 0.000 claims abstract description 44
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract description 29
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940039781 leptin Drugs 0.000 claims abstract description 13
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims abstract description 11
- 102000016267 Leptin Human genes 0.000 claims abstract description 10
- 108010092277 Leptin Proteins 0.000 claims abstract description 10
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 8
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 8
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 35
- 102000003910 Cyclin D Human genes 0.000 claims description 22
- 102000006311 Cyclin D1 Human genes 0.000 claims description 21
- 108010058546 Cyclin D1 Proteins 0.000 claims description 21
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 claims description 14
- 102000047723 human CCND1 Human genes 0.000 claims description 13
- 239000012679 serum free medium Substances 0.000 claims description 7
- 230000000638 stimulation Effects 0.000 claims description 2
- 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 claims 2
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 15
- 108020004707 nucleic acids Proteins 0.000 abstract description 14
- 102000039446 nucleic acids Human genes 0.000 abstract description 14
- 230000003394 haemopoietic effect Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 102000008108 Osteoprotegerin Human genes 0.000 abstract 2
- 108010035042 Osteoprotegerin Proteins 0.000 abstract 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 abstract 2
- -1 OPG-Fc Chemical compound 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 32
- 239000002609 medium Substances 0.000 description 25
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 23
- 239000013604 expression vector Substances 0.000 description 23
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 20
- 230000001105 regulatory effect Effects 0.000 description 19
- 238000001890 transfection Methods 0.000 description 17
- 102100031939 Erythropoietin Human genes 0.000 description 16
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 15
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 15
- 229960000485 methotrexate Drugs 0.000 description 15
- 238000001262 western blot Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 13
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 12
- ADXLZWYVJHRTST-BIWMIDHDSA-N (1r,2r,3s,4r,5s,6s)-2-amino-6-(hydroxymethyl)-7-oxabicyclo[4.1.0]heptane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](N)[C@H]2O[C@]21CO ADXLZWYVJHRTST-BIWMIDHDSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108010019673 Darbepoetin alfa Proteins 0.000 description 10
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003306 harvesting Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 6
- 210000004128 D cell Anatomy 0.000 description 6
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 235000011010 calcium phosphates Nutrition 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 238000012270 DNA recombination Methods 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 4
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 108020001096 dihydrofolate reductase Proteins 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 108090000257 Cyclin E Proteins 0.000 description 2
- 102000003909 Cyclin E Human genes 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000052781 human TNFRSF11B Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150002621 EPO gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 1
- 101000801195 Homo sapiens TLE family member 5 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000049953 human LEP Human genes 0.000 description 1
- 102000056245 human TLE5 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (38)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 다음을 포함하는 포유동물 세포 :(a) 사이클린 D 유전자 산물에 대한 유전자 구성물을 삽입하기 전의 세포에서의 사이클린 D 유전자 산물의 발현 수준보다 2 배 내지 5 배 높은 수준으로 세포에서 기능상 발현되는, 사이클린 D 유전자 산물에 대한 삽입된 유전자 구성물 ; 및(b) 목적 단백질에 대한 유전자 구성물을 삽입하기 전의 세포에서의 목적 단백질의 발현 수준보다 2 배 내지 5 배 높은 수준으로 세포에서 발현되는, 목적 단백질에 대한 삽입된 유전자 구성물.
- 제 21 항에 있어서, 세포는 CHO 세포임을 특징으로 하는 세포.
- 제 21 항에 있어서, 세포는 AM-1 세포임을 특징으로 하는 세포.
- 제 21 항에 있어서, 사이클린 D 유전자 산물은 포유동물 사이클린 D1 을 포함함을 특징으로 하는 세포.
- 제 21 항에 있어서, 사이클린 D 유전자 산물은 인체 사이클린 D 를 포함함을 특징으로 하는 세포.
- 제 21 항에 있어서, 사이클린 D 유전자 산물은 인체 사이클린 D1 을 포함함을 특징으로 하는 세포.
- 제 21 항에 있어서, 목적 단백질은 에리트로포이에틴(EPO)-관련 단백질, 오스테오프로게테린(OPG)-관련 단백질 또는 렙틴-관련 단백질임을 특징으로 하는 세포.
- 제 21 항에 있어서, 목적 단백질은 EPO, 신규 조혈 자극 단백질(Navel Erythropoiesis Stimulation Protein ; NESP), OPG, OPG-Fc, 렙틴 또는 Fc-렙틴임을 특징으로 하는 세포.
- 제 22 항에 있어서, 세포는 무혈청 배지에서 성장할 수 있음을 특징으로 하는 세포.
- 다음 단계를 포함하는 목적 단백질의 생산 방법 :a. 다음을 포함하는 진핵 세포를 생산하고1. 사이클린 D 유전자 산물에 대한 유전자 구성물을 삽입하기전의 세포에서의 사이클린 D 유전자의 발현 수준보다 2 배내지 5 배 높은 수준으로 세포에서 기능상 발현되는,사이클린 D 유전자 산물에 대한 삽입된 유전자 구성물 및2. 목적 단백질에 대한 유전자 구성물을 삽입하기 전의세포에서의 목적 단백질의 발현 수준보다 2 배 내지 5 배높은 수준으로 세포에서 기능상 발현되는, 목적 단백질에 대한삽입된 유전자 구성물 ;b. 목적 단백질의 발현과 사이클린 D 유전자 산물의 기능상 발현을 가능하게 하는 조건하에서 세포를 배양하며 ;c. 목적 단백질을 분리한다.
- 제 30 항에 있어서, 세포는 CHO 세포임을 특징으로 하는 방법.
- 제 30 항에 있어서, 세포는 AM-1 세포임을 특징으로 하는 방법.
- 제 30 항에 있어서, 사이클린 D 유전자 산물은 포유동물 사이클린 D1 을 포함함을 특징으로 하는 방법.
- 제 30 항에 있어서, 사이클린 D 유전자 산물은 인체 사이클린 D 를 포함함을 특징으로 하는 방법.
- 제 30 항에 있어서, 사이클린 D 유전자 산물은 인체 사이클린 D1 을 포함함을 특징으로 하는 방법.
- 제 30 항에 있어서, 목적 단백질은 EPO-관련 단백질, OPG-관련 단백질 또는 렙틴-관련 단백질임을 특징으로 하는 방법.
- 제 30 항에 있어서, 목적 단백질은 EPO, NESP, OPG, OPG-Fc, 렙틴 또는 Fc-렙틴임을 특징으로 하는 방법.
- 제 31 항에 있어서, 세포는 무혈청 배지에서 성장할 수 있음을 특징으로 하는 방법.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9608698P | 1998-08-11 | 1998-08-11 | |
US60/096,086 | 1998-08-11 | ||
US09/371,309 | 1999-08-10 | ||
US09/371,309 US6210924B1 (en) | 1998-08-11 | 1999-08-10 | Overexpressing cyclin D 1 in a eukaryotic cell line |
PCT/US1999/018213 WO2000009714A1 (en) | 1998-08-11 | 1999-08-11 | Overexpression of desired proteins in eukaryotic cells mediated by cyclin d1 overexpression |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020013462A KR20020013462A (ko) | 2002-02-20 |
KR100502701B1 true KR100502701B1 (ko) | 2005-07-22 |
Family
ID=22255220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-7001843A KR100502701B1 (ko) | 1998-08-11 | 1999-08-11 | 사이클린 d1 과발현에 의해 매개되는, 진핵 세포에서의목적 단백질의 과발현 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6210924B1 (ko) |
EP (1) | EP1105507B1 (ko) |
JP (1) | JP4562915B2 (ko) |
KR (1) | KR100502701B1 (ko) |
CN (1) | CN1151263C (ko) |
AT (1) | ATE374827T1 (ko) |
AU (1) | AU747640B2 (ko) |
CA (1) | CA2338820C (ko) |
CY (1) | CY1106987T1 (ko) |
DE (1) | DE69937243T2 (ko) |
DK (1) | DK1105507T3 (ko) |
ES (1) | ES2291038T3 (ko) |
HU (1) | HU230247B1 (ko) |
PT (1) | PT1105507E (ko) |
WO (1) | WO2000009714A1 (ko) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
PT2087908T (pt) | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
EP1414517A4 (en) * | 2001-06-26 | 2008-02-06 | Photomed Technologies Inc | MULTIPLE WAVELENGTH ILLUMINATOR |
KR100427299B1 (ko) * | 2001-08-10 | 2004-04-14 | 한국생명공학연구원 | 인체 골 재흡수 억제인자(hOPG)를 생산하는 재조합플라스미드 pGHOPG(KCTC 1019BP) |
CA2481074A1 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
NZ593428A (en) | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
EP1739179A1 (en) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
EP2500414A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
SG174804A1 (ko) | 2006-09-13 | 2011-10-28 | Abbott Lab | |
CA2676036A1 (en) * | 2007-02-02 | 2008-08-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
MX340971B (es) | 2009-11-23 | 2016-08-02 | Amgen Inc * | Fragmento cristalizable (fc) de anticuerpo monomerico. |
JP5997140B2 (ja) * | 2010-07-05 | 2016-09-28 | ウニヴェルシテート フュア ボーデンクルトゥーア ウィーン | 生産細胞株 |
MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
EP2847219A1 (en) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anti-erythropoietin antibodies |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
MX2016002870A (es) | 2013-09-05 | 2017-02-23 | Amgen Inc | Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles. |
US10435464B1 (en) | 2014-09-05 | 2019-10-08 | Coherus Biosciences, Inc. | Methods for making recombinant proteins |
WO2016044224A1 (en) | 2014-09-15 | 2016-03-24 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
JP6749898B2 (ja) | 2014-10-15 | 2020-09-02 | アムジエン・インコーポレーテツド | 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント |
CN105669863B (zh) | 2014-12-05 | 2019-09-13 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
WO2017058944A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors |
US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
TWI826351B (zh) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧(杭州)生物醫藥有限公司 | R抗體,其藥物組合物及其應用 |
US20190367611A1 (en) | 2017-02-01 | 2019-12-05 | CentryMed Pharmaceutical Inc. | Monomeric human igg1 fc and bispecific antibodies |
CN117126279A (zh) | 2018-03-20 | 2023-11-28 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
JP2021521854A (ja) | 2018-05-01 | 2021-08-30 | アムジエン・インコーポレーテツド | 調節されたグリカンプロファイルを有する抗体 |
CN110655577A (zh) | 2018-06-13 | 2020-01-07 | 鸿运华宁(杭州)生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质,以及其药物组合物和应用 |
MA56110A (fr) | 2019-06-07 | 2022-04-13 | Amgen Inc | Constructions de liaison bispécifiques à lieurs clivables de manière sélective |
CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
IL303205A (en) | 2020-12-03 | 2023-07-01 | Amgen Inc | IMMUNOGLOBULINE constructs with multiple binding domains |
CN115141276A (zh) | 2021-03-31 | 2022-10-04 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用 |
AU2022287014A1 (en) | 2021-06-04 | 2023-12-07 | Amgen Inc. | T cell engager molecules and uses thereof |
CN113698466B (zh) * | 2021-07-30 | 2023-07-14 | 山东农业大学 | Ccnd1在制备禽反转录病毒生产增强剂中的应用 |
WO2024092033A1 (en) | 2022-10-26 | 2024-05-02 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
IL79176A (en) | 1985-06-20 | 1992-06-21 | Kirin Amgen Inc | Process for the recovery of erythropoietin from a fluid |
US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
JP2983629B2 (ja) | 1989-10-13 | 1999-11-29 | キリン―アムジエン・インコーポレイテツド | エリスロポエチンイソフォーム |
JPH06117187A (ja) | 1992-10-08 | 1994-04-26 | Iseki Tory Tech Inc | シールド掘削機 |
US5514571A (en) | 1993-08-05 | 1996-05-07 | University Technologies International Inc. | Cyclin D1 negative regulatory activity |
US5521066A (en) | 1993-09-13 | 1996-05-28 | Bristol-Myers Squibb Company | Periplasmic membrane-bound system for detecting protein-protein interactions |
AU1552995A (en) | 1993-12-17 | 1995-07-03 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
ES2216055T3 (es) | 1995-08-17 | 2004-10-16 | Amgen Inc | Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob. |
NZ512083A (en) | 1995-11-22 | 2003-02-28 | Amgen Inc | Methods of increasing lean tissue mass using OB protein compositions |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
GB9608143D0 (en) * | 1996-04-19 | 1996-06-26 | Ver Nl Kanker Inst | Assay |
-
1999
- 1999-08-10 US US09/371,309 patent/US6210924B1/en not_active Expired - Lifetime
- 1999-08-11 WO PCT/US1999/018213 patent/WO2000009714A1/en active IP Right Grant
- 1999-08-11 DE DE69937243T patent/DE69937243T2/de not_active Expired - Lifetime
- 1999-08-11 HU HU0103485A patent/HU230247B1/hu unknown
- 1999-08-11 CN CNB998118990A patent/CN1151263C/zh not_active Expired - Lifetime
- 1999-08-11 CA CA002338820A patent/CA2338820C/en not_active Expired - Lifetime
- 1999-08-11 KR KR10-2001-7001843A patent/KR100502701B1/ko not_active IP Right Cessation
- 1999-08-11 AU AU55546/99A patent/AU747640B2/en not_active Expired
- 1999-08-11 EP EP99942098A patent/EP1105507B1/en not_active Expired - Lifetime
- 1999-08-11 AT AT99942098T patent/ATE374827T1/de active
- 1999-08-11 ES ES99942098T patent/ES2291038T3/es not_active Expired - Lifetime
- 1999-08-11 PT PT99942098T patent/PT1105507E/pt unknown
- 1999-08-11 DK DK99942098T patent/DK1105507T3/da active
- 1999-08-11 JP JP2000565148A patent/JP4562915B2/ja not_active Expired - Lifetime
-
2007
- 2007-11-08 CY CY20071101438T patent/CY1106987T1/el unknown
Non-Patent Citations (1)
Title |
---|
Cancer Research, Vol.56(1):36-39(1995. 6) * |
Also Published As
Publication number | Publication date |
---|---|
EP1105507B1 (en) | 2007-10-03 |
HUP0103485A2 (hu) | 2002-01-28 |
HU230247B1 (hu) | 2015-11-30 |
JP4562915B2 (ja) | 2010-10-13 |
EP1105507A1 (en) | 2001-06-13 |
AU747640B2 (en) | 2002-05-16 |
WO2000009714A1 (en) | 2000-02-24 |
CA2338820A1 (en) | 2000-02-24 |
CN1322253A (zh) | 2001-11-14 |
JP2003524378A (ja) | 2003-08-19 |
ATE374827T1 (de) | 2007-10-15 |
CY1106987T1 (el) | 2012-09-26 |
HUP0103485A3 (en) | 2010-01-28 |
KR20020013462A (ko) | 2002-02-20 |
PT1105507E (pt) | 2007-12-07 |
US6210924B1 (en) | 2001-04-03 |
CA2338820C (en) | 2005-10-18 |
WO2000009714A9 (en) | 2000-05-18 |
DK1105507T3 (da) | 2007-11-05 |
AU5554699A (en) | 2000-03-06 |
CN1151263C (zh) | 2004-05-26 |
DE69937243T2 (de) | 2008-07-03 |
ES2291038T3 (es) | 2008-02-16 |
DE69937243D1 (de) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100502701B1 (ko) | 사이클린 d1 과발현에 의해 매개되는, 진핵 세포에서의목적 단백질의 과발현 | |
AU2007278368B2 (en) | Regulatory nucleic acid elements | |
US5578461A (en) | Gene manipulation and expression using genomic elements | |
JP3495375B2 (ja) | 真核生物発現システムの発現増大配列エレメント(ease) | |
CN102165060B (zh) | 新的调控组件 | |
Mortensen et al. | Embryonic stem cells lacking a functional inhibitory G-protein subunit (alpha i2) produced by gene targeting of both alleles. | |
Ye et al. | Identification of the promoter region of human interleukin 1 type I receptor gene: multiple initiation sites, high G+ C content, and constitutive expression. | |
US20100120089A1 (en) | A novel vector and expression cell line for mass production of recombinant protein and a process of producing recombinant protein using same | |
EP0516787B1 (en) | Expression systems | |
ES2213925T3 (es) | Seleccion entre positivos y negativos en el caso de la recombinacion homologa. | |
KR100259933B1 (ko) | 게놈 엘리먼트를 이용한 유전자 조작 및 발현방법 | |
US9476081B2 (en) | Method for producing protein | |
CA2328506A1 (en) | Modifying the expression of the fsh beta gene by homologous recombination | |
EP0546333B1 (en) | Cloned DNA having enhancer activity, recombinant vector comprising the same and process for producing gene product using the same | |
Hofstetter et al. | A new genetic approach for studying hormonal regulation of urokinase-type plasminogen activator gene expression in LLC-PK1 cells | |
KR101030978B1 (ko) | 동물세포용 재조합 발현벡터 | |
Sala et al. | Inhibition of erythro-myeloid differentiation by constitutive expression of a DNA binding-deficient c-myb mutant: implication for c-myb function | |
WO1996017933A2 (en) | Dna encoding a cell growth inhibiting factor and its product | |
MXPA01001238A (en) | Overexpression of desired proteins in eukaryotic cells mediated by cyclin d1 overexpression | |
WO1992021763A1 (en) | Enhancement of expression by gene targeting in endogenous retrovirus-like sequences | |
WO1988009809A2 (en) | Cell system for expression of recombinant protein without production of virus | |
US9315565B2 (en) | Method for producing protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130620 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140701 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150618 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160616 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170616 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190617 Year of fee payment: 15 |
|
EXPY | Expiration of term |